The Canadian Inflammatory Myopathy Study: a network to advance research, training, and knowledge translation in inflammatory myopathies.

A registry to expand and facilitate research on inflammatory myopathies in Canada.

6 Recruiting Centers

> 320 myositis patients

> 700 visits

> 1800 Serum Samples Biobanked

Our Strengths

The strengths of this study include:

A prospective, longitudinal and multi-centered inception cohort of patients with autoimmune myopathies.

A multi-disciplinary team with experts from a wide variety of disciplines, including pathology, respirology, radiology, and biostatistics.

The participation of basic scientists to pursue translational opportunities.

The commitment to building capacity by training highly qualified professionals.

Well-developed relationships with patient organizations to help identify research priorities and disseminate knowledge

Patients eligible for CIMS are all consecutive incident patients with an inflammatory myopathy

Patients included in CIMS received a diagnosis of inflammatory myopathy by their physician. This can include patients with dermatomyositis, overlap myositis, anti-synthetase syndrome, immune mediated necrotizing myopathy, polymyositis or inclusion body myositis. The data collection protocol of CIMS includes the measures developed by the International Myositis Assessment and Clinical Studies (IMACS) at the National Institute of Health (NIH) as well as several patient-reported outcome measures.